If you’re a dividend investor seeking consistency, low volatility, and reliable income, this healthcare stock checks all the right boxes. With a remarkably low beta of just 0.41, it offers a smoother ride than the broader market, helping to buffer portfolio swings while delivering a forward dividend yield of 3.16%. Add to that a 50+ year history of uninterrupted dividend increases, a manageable 48% payout ratio, and top-tier liquidity of $1.2 billion in daily volume, and you have a rare combination of income stability and risk control.
This company operates in the heart of the global healthcare sector, with diversified exposure to high-growth therapeutic areas and medical technologies. Its pharmaceutical division is fueled by a broad base of treatments targeting immunology, oncology, and neuroscience, while its device business is making waves in cardiovascular innovation and surgical advancements. These engines are supported by a cash-rich balance sheet and a robust pipeline of late-stage assets. That said, the company is not without its challenges—biosimilar competition is actively weighing on legacy drug sales, and cost pressures tied to macro inflation and policy changes are squeezing margins in its devices division. Still, management is targeting a 300-basis-point margin improvement by year-end, signaling a disciplined approach to execution.
From low-risk profile to long-term income potential, this stock remains a core holding in our Quality Dividends Portfolio. If you want to understand what keeps this giant on our Buy list and how it balances growth with stability, dive into the full article to uncover the full picture.
